

PERSONAL INFORMATION

Family name: Lasorsa

First name: Vito Alessandro

Date of birth: 29/11/1979 Terlizzi (BA, Italy)

Nationality: Italian

Fiscal code: LSRVLS79S29L109K

Address: Strada Esterna Lagacchiola, 30 – 70033 Corato (BA, Italy)

Mobile: +39 3281452264

Mail: lasorsa.alessandro@gmail.com; lasorsa@ceinge.unina.it

ORCID ID: orcid.org/0000-0002-9552-7192 | Scopus Author ID: 57189068383

EDUCATION

July 2012 | Master's degree in Biology, University of Bari "Aldo Moro"

November 2012 | Enabled to the profession of Biologist by passing the Italian State Certification Exam.

November 2013 | Second level Master's degree, University of Bari "Aldo Moro"

March 2021 | PhD, University of Napoli "Federico II"

CURRENT POSITIONS

April 2021 to date | Permanent, full-time employed. Professional figure: Bioinformatician. Professional profile: Scientific, Sanitary. Professional level: First. The Bioinformatics Service for NGS, CEINGE Biotechnologie Avanzate Franco Salvatore scarl, Napoli (Italy).

WORK EXPERIENCES

April 2014 – December 2016 | Research Fellow at CEINGE-Biotechnologie Avanzate, Napoli (Italy). Funding: Fondazione italiana per la lotta al Neuroblastoma.

January 2017 – March 2021 | Research Fellow at CEINGE Biotechnologie Avanzate, Napoli (Italy). Funding: AIRC.

PERSONAL STATEMENT

I am a Computational Biologist with a very strong interest in Human Genetics and Genomics. In particular, I'm interested in studying the genetic bases of complex diseases including cancer. As a bioinformatician I'm involved in collaborating with diverse research groups to build and optimize analysis pipelines going from the initial quality checks of the data to the presentation of the final results and preparation of research articles.

TECHNICAL COMPETENCES

Mac OS (preferred), Windows OS and Linux OS. Advanced command of Microsoft Office. Bash shell and Bash scripting. Advanced knowledge of R platform for statistical computing and of a number of specific programs and command line tools used in the analysis of Next Generation Sequencing data.

SCIENTIFIC OUTPUT (indexes extracted from Pubmed and Google Scholar)

Scientific publications: 47 | First authorship: 6 | Total citations: 989 | H-index: 19 | Total Impact Factor: 293.369 | Mean Impact Factor: 6.4 | Talks at conferences: 6 | Posters at conferences: 8

LIST OF PUBLICATIONS (PUBMED INDEXED)

- **The Non-Coding Regulatory Variant rs2863002 at chr11p11.2 Increases Neuroblastoma Risk by Affecting HSD17B12 Expression and Lipid Metabolism.** Maiorino T, Avitabile M, Aievola V, Montella A, **Lasorsa VA**, Bonfiglio F, Cantalupo M, Cantalupo S, Estinto G, Tirelli M, Morini M, Ardito M, Eva A, V, Mauriello L, Caterino M, Ruoppolo M, Maris JM, Diskin SJ, Iolascon A, Capasso M. *Advanced Science*. 2025 Jun 17. PMID: 40525640. IF: 14.1.
- **CTpredX: Enhancing missense variant pathogenicity prediction in childhood cancer predisposition genes.** Bonfiglio F, **Lasorsa VA**, Pirozzi G, Iolascon A, Capasso M. *Genes & Diseases*. 2025 Apr 28. IF: 9.4.
- **Regulatory non-coding somatic mutations as drivers of neuroblastoma.** Montella A, Tirelli M, **Lasorsa VA**, Aievola V, Cerbone V, Manganiello R, Iolascon A, Capasso M. *Br J Cancer*. 2025 Jan 23. PMID: 39843641. IF: 6.4.
- **RAS signaling pathway is essential in regulating PIEZO1-mediated hepatic iron overload in dehydrated hereditary stomatocytosis.** Rosato BE, D'Onofrio V, Marra R, Nostro A, Esposito FM, Iscaro A, **Lasorsa VA**, Capasso M, Iolascon A, Russo R, Andolfo I. *Am J Hematol*. 2024 Nov 18. PMID: 39558179. IF: 10.1.
- **Six months of different exercise type in sedentary primary schoolchildren: impact on physical fitness and saliva microbiota composition.** Mancini A, Vitucci D, **Lasorsa VA**, Lupo C, Brustio PR, Capasso M, Orrù S, Rainoldi A, Schena F, Buono P. *Front Nutr*. 2024 Oct 24. PMID: 39512522. IF: 4.0.
- **Best practices for germline variant and DNA methylation analysis of second- and third-generation sequencing data.** Bonfiglio F, Legati A, **Lasorsa VA**, Palombo F, De Riso G, Isidori F, Russo S, Furini S, Merla G, Coppedè F, Tartaglia M; Omics Sciences - Bioinformatics and Epigenetics Working Groups of the Italian Society of Human Genetics (SIGU); Bruselles A, Pippucci T, Ciolfi A, Pinelli M, Capasso M. *Hum Genomics*. 2024 Nov 5. PMID: 39501379. IF: 3.8.
- **Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication.** de Antonellis P, Ferrucci V, Miceli M, Bibbo F, Asadzadeh F, Gorini F, Mattivi A, Boccia A, Russo R, Andolfo I, **Lasorsa VA**, Cantalupo S, Fusco G, Viscardi M, Brandi S, Cerino P, Monaco V, Choi DR, Cheong JH, Iolascon A, Amente S, Monti M, Fava LL, Capasso M, Kim HY, Zollo M. *EMBO Rep*. 2024 May 30. PMID: 38816514. IF: 6.5.
- **Exploring the role of HLA variants in neuroblastoma susceptibility through whole exome sequencing.** Bonfiglio F, **Lasorsa VA**, Aievola V, Cantalupo S, Morini M, Ardito M, Conte M, Fragola M, Eva A, Corrias MV, Iolascon A, Capasso M. *HLA*. 2024 May 15. PMID: 38747019. IF: 5.9.
- **The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.** Giordano C, Marrone L, Romano S, Della Pepa GM, Donzelli CM, Tufano M, Capasso M, **Lasorsa VA**, Quintavalle C, Guerri G, Martucci M, Auricchio A, Gessi M, Sala E, Olivi A, Romano MF, Gaudino S. *Cancer Res Commun*. 2024 May 16. PMID: 38651817. IF: 2.0.
- **From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.** Capasso M, Brignole C, **Lasorsa VA**, Bensa V, Cantalupo S, Sebastiani E, Quattrone A, Ciampi E, Avitabile M, Sementa AR, Mazzocco K, Cafferata B, Gaggero G, Vellone VG, Cilli M, Calarco E, Giusto E, Perri P, Aveic S, Fruci D, Tondo A, Luksch R, Mura R, Rabusin M, De Leonardi F, Cellini M, Coccia P, Iolascon A, Corrias MV, Conte M, Garaventa A, Amoroso L, Ponzoni M, Pastorino F. *J Transl Med*. 2024 Feb 13. PMID: 38351008. IF: 6.1.
- **Impact of active lifestyle on the primary school children saliva microbiota composition.** Mancini A, Cerulli C, Vitucci D, **Lasorsa VA**, Parente D, Di Credico A, Orrù S, Brustio PR, Lupo C, Rainoldi A, Schena F, Capasso M, Buono P. *Front Nutr*. 2023 Aug 10. PMID: 37671197. IF: 4.0.
- **Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.** Pastorino F, Capasso M, Brignole C, **Lasorsa VA**, Bensa V, Perri P, Cantalupo S, Giglio S, Provenzi M, Rabusin M, Pota E, Cellini M, Tondo A, De Ioris MA, Sementa AR, Garaventa A, Ponzoni M, Amoroso L. *Cancers (Basel)*. 2023 Jan 17. PMID: 36765519. IF: 4.5.
- **Inherited rare variants in homologous recombination and neurodevelopmental genes are associated with increased risk of neuroblastoma.** Bonfiglio F, **Lasorsa VA**, Cantalupo S, D'Alterio G, Aievola V, Boccia A, Ardito M, Furini S, Renieri A, Morini M, Stainczyk S, Westermann F, Paoletta G, Eva A, Iolascon A, Capasso M. *EBioMedicine*. 2022 Dec 6. PMID: 36493725. IF: 11.205.
- **CFDP1 is a neuroblastoma susceptibility gene that regulates transcription factors of the noradrenergic cell identity.** Formicola D, **Lasorsa VA**, Cantalupo S, Testori A, Cardinale A, Avitabile M, Diskin S, Iolascon A, Capasso M. *HGG Adv*. 2022 Nov 3. PMID: 36425957. IF: 4.4.
- **Therapeutic Targeting of ALK in Neuroblastoma: Experience of Italian Precision Medicine in Pediatric Oncology.** Pastorino F, Capasso M, Brignole C, **Lasorsa VA**, Bensa V, Perri P, Cantalupo S, Giglio S, Provenzi M, Rabusin M, Pota E, Cellini M, Tondo A, De Ioris MA, Sementa AR, Garaventa A, Ponzoni M, Amoroso L. *Cancers (Basel)*. 2023 Jan 17. PMID: 36765519. IF: 6.575.
- **Italian Precision Medicine in Pediatric Oncology: Moving beyond Actionable Alterations.** Pastorino F, Capasso M,

Brignole C, Giglio S, Bensa V, Cantalupo S, **Lasorsa VA**, Tondo A, Mura R, Sementa AR, Garaventa A, Ponzoni M, Amoroso L. *Int J Mol Sci*. 2022 Sep 23. PMID: 36232538. IF: 6.208.


- **Single-cell transcriptomics of neuroblastoma identifies chemoresistance-associated genes and pathways.** Avitabile M, Bonfiglio F, Aievola V, Cantalupo S, Maiorino T, **Lasorsa VA**, Domenicotti C, Marengo B, Zbyněk H, Vojtěch A, Iolascon A, Capasso M. *Comput Struct Biotechnol J*. 2022 Aug 18. PMID: 36051886. IF: 7.271.
- **Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals.** D'Alterio G, **Lasorsa VA**, Bonfiglio F, Cantalupo S, Rosato BE, Andolfo I, Russo R, Esposito U, Frisso G, Abete P, Cassese GM, Servillo G, Gentile I, Piscopo C, Della Monica M, Fiorentino G, Boccia A, Paoletta G, Ferrucci V, de Antonellis P, Siciliano R, Asadzadeh F, Cerino P, Buonerba C, Pierri B, Zollo M, Iolascon A, Capasso M. *Genet Med*. 2022 Aug 24. PMID: 35511137. IF: 8.864.
- **FGFR1 is a potential therapeutic target in neuroblastoma.** Cimmino F, Montella A, Tirelli M, Avitabile M, **Lasorsa VA**, Visconte F, Cantalupo S, Maiorino T, De Angelis B, Morini M, Castellano A, Locatelli F, Capasso M, Iolascon A. *Cancer Cell Int*. 2022 Apr 29. PMID: 35488346. IF: 5.149.
- **Methylome Analysis in Nonfunctioning and GH-Secreting Pituitary Adenomas.** Giuffrida G, D'Argenio V, Ferraù F, **Lasorsa VA**, Polito F, Aliquò F, Ragonese M, Cotta OR, Alessi Y, Oteri R, Di Maggio F, Asmundo A, Romeo PD, Spagnolo F, Pastore L, Angileri FF, Capasso M, Cannavò S, Aguenouz M. *Front Endocrinol*. 2022 Mar 30. PMID: 35432200. IF: 5.555.
- **Somatic mutations enriched in cis-regulatory elements affect genes involved in embryonic development and immune system response in neuroblastoma.** **Lasorsa VA**, Montella A, Cantalupo S, Tirelli M, de Torres C, Aveic S, Tonini GP, Iolascon A, Capasso M. *Cancer Res*. 2022 Jan 31. PMID: 35101866. IF: 12.843.
- **A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine.** Paparo L, Maglio MA, Cortese M, Bruno C, Capasso M, Punzo E, Ferrucci V, **Lasorsa VA**, Viscardi M, Fusco G, Cerino P, Romano A, Troncone R, Zollo M. *Molecules*. 2022 Jan 27. PMID: 35164139. IF: 4.412.
- **Functional annotation and investigation of the 10q24.33 melanoma risk locus identifies a common variant that influences transcriptional regulation of OBFC1.** Cardinale A, Cantalupo S, **Lasorsa VA**, Montella A, Cimmino F, Succio M, Vermeulen M, Baltissen MP, Esposito M, Avitabile M, Formicola D, Testori A, Bonfiglio F, Ghiorzo P, Scalvenzi M, Ayla F, Zambrano N, Iles MM, Xu M, Law MH, Brown KM, Iolascon A, Capasso M. *Hum Mol Genet*. 2021 Oct 4. PMID: 34605909. IF: 6.15.
- **The TNFRSF13C H159Y Variant Is Associated with Severe COVID-19: A Retrospective Study of 500 Patients from Southern Italy.** Russo R, Andolfo I, **Lasorsa VA**, Cantalupo S, Marra R, Frisso G, Abete P, Cassese GM, Servillo G, Esposito G, Gentile I, Piscopo C, Della Monica M, Fiorentino G, Russo G, Cerino P, Buonerba C, Pierri B, Zollo M, Iolascon A, Capasso M. *Genes (Basel)*. 2021 Jun 8. PMID: 34201032. IF: 3.96.
- **Regulatory Noncoding and Predicted Pathogenic Coding Variants of CCR5 Predispose to Severe COVID-19.** Cantalupo S, **Lasorsa VA**, Russo R, Andolfo I, D'Alterio G, Rosato BE, Frisso G, Abete P, Cassese GM, Servillo G, Gentile I, Piscopo C, Della Monica M, Fiorentino G, Russo G, Cerino P, Buonerba C, Pierri B, Zollo M, Iolascon A, Capasso M. *Int J Mol Sci*. 2021 May 20. PMID: 34065289. IF: 6.208.
- **Estimating asymptomatic SARS-CoV-2 infections in a geographic area of low disease incidence.** Caturano V, Manti B, Carbone F, **Lasorsa VA**, Colicchio R, Capasso M, Leonardi A, Matarese G, Russo T, Salvatore P. *BMC Infect Dis*. 2021 Apr 15. PMID: 33853532. IF: 3.629.
- **Common variants at 21q22.3 locus influence MX1 and TMPRSS2 gene expression and susceptibility to severe COVID-19.** Andolfo I, Russo R, **Lasorsa VA**, Cantalupo S, Rosato BE, Bonfiglio F, Frisso G, Abete P, Cassese GM, Servillo G, Esposito G, Gentile I, Piscopo C, Villani R, Fiorentino G, Cerino P, Buonerba C, Pierri B, Zollo M, Iolascon A, Capasso M. *iScience*. 2021 Mar 17. PMID: 33748697. IF: 6.107.
- **A targeted gene panel for circulating tumor DNA sequencing in neuroblastoma.** Cimmino F, **Lasorsa VA**, Vertella S, Iolascon A, Capasso M. *Front Oncol*. 2020 Dec 14. PMID: 33381456. IF: 5.738.
- **Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.** Jemaà M, Sime W, Abassi Y, **Lasorsa VA**, Bonne Køhler J, Michaelis M, Cinatl J Jr, Capasso M, Massoumi R. *Int J Mol Sci*. 2020 Sep 16. PMID: 32948088. IF: 6.208.
- **Discovery of epi-Enprioline as a Novel Drug for the Treatment of Vincristine Resistant Neuroblastoma.** Sime W, Jemaà M, Abassi Y, **Lasorsa VA**, Bonne Køhler J, Hansson K, Bexell D, Michaelis M, Cinatl J Jr, Strand D, Capasso M, Massoumi R. *Int J Mol Sci*. 2020 Sep 8. PMID: 32911859. IF: 6.208.
- **Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease TMPRSS2 in Different Populations.** Russo R, Andolfo I, **Lasorsa VA**, Iolascon A, Capasso M. *Front Genet*. 2020 Aug 4. PMID: 32849840. IF: 4.772.
- **Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.** Andolfo I, **Lasorsa VA**, Manna F, Rosato BE, Formicola D, Iolascon A, Capasso M. *J Cell Mol Med*. 2020 Apr 26. PMID: 32336043. IF: 5.214.

- **miR-622 is a novel potential biomarker of breast carcinoma and impairs motility of breast cancer cells through targeting NUA1 kinase.** Orlandella FM, Mariniello RM, Mirabelli P, De Stefano AE, Iervolino PLC, **Lasorsa VA**, Capasso M, Giannatiempo R, Rongo M, Incoronato M, Messina F, Salvatore M, Soricelli A, Salvatore G. *Br J Cancer*. 2020 May 18. PMID: 32418991. IF: 7.503.
- **19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis.** **Lasorsa VA**, Cimmino F, Ognibene M, Mazzocco K, Erminio G, Morini M, Conte M, Iolascon A, Pezzolo A, Capasso M. *NPJ Genom Med*. 2020 Apr 15. PMID: 32337068. IF: 8.617.
- **Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma.** Cimmino F, Avitabile M, **Lasorsa VA**, Pezone L, Cardinale A, Montella A, Cantalupo S, Iolascon A, Capasso M. *J Cancer*. 2020 Jan 14. PMID: 32047556. IF: 4.207.
- **Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.** Avitabile M, **Lasorsa VA**, Cantalupo S, Cardinale A, Cimmino F, Montella A, Capasso D, Haupt R, Amoroso L, Garaventa A, Quattrone A, Corrias MV, Iolascon A, Capasso M. *J Cell Mol Med*. 2020 Feb 27. PMID: 32103589. IF: 5.214.
- **Transcription factors involved in tumorigenesis are over-represented in mutated active DNA binding sites in neuroblastoma.** Capasso M, **Lasorsa VA**, Cimmino F, Avitabile M, Cantalupo S, Montella A, De Angelis B, Morini M, de Torres C, Castellano A, Locatelli F, Iolascon A. *Cancer Res*. 2019 Nov 29. PMID: 31784426. IF: 12.843.
- **Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.** Amoroso L, Ognibene M, Morini M, Conte M, Di Cataldo A, Tondo A, D'Angelo P, Castellano A, Garaventa A, **Lasorsa VA**, Podestà M, Capasso M, Pezzolo A. *Genes Chromosomes Cancer*. 2019 Nov 22. PMID: 31756773. IF: 4.67.
- **Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene.** Avitabile M, Succio M, Testori A, Cardinale A, Vaksman Z, **Lasorsa VA**, Cantalupo S, Esposito M, Cimmino F, Montella A, Formicola D, Koster J, Andreotti V, Ghiorzo P, Romano MF, Staibano S, Scalvenzi M, Ayala F, Hakonarson H, Corrias MV, Devoto M, Law MH, Iles MM, Brown K, Diskin S, Zambrano N, Iolascon A, Capasso M. *Carcinogenesis*. 2019 Sep 7. PMID: 31605138. IF: 4.944.
- **Exploring Shared Susceptibility between Two Neural Crest Cells Originating Conditions: Neuroblastoma and Congenital Heart Disease.** Testori A, **Lasorsa VA**, Cimmino F, Cantalupo S, Cardinale A, Avitabile M, Limongelli G, Russo MG, Diskin S, Maris J, Devoto M, Keavney B, Cordell HJ, Iolascon A, Capasso M. *Genes (Basel)*. 2019 Aug 30. PMID: 31480262. IF: 3.96.
- **HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia.** Cimmino F, Avitabile M, **Lasorsa VA**, Montella A, Pezone L, Cantalupo S, Visconte F, Corrias MV, Iolascon A, Capasso M. *BMC Med Genet*. 2019 Feb 26. PMID: 30808328. IF: 2.01.
- **Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.** Esposito MR, Binatti A, Pantile M, Coppe A, Mazzocco K, Longo L, Capasso M, **Lasorsa VA**, Luksch R, Bortoluzzi S, Tonini GP. *Int J Cancer*. 2018 Nov 15. PMID: 29992558. IF: 7.396.
- **BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.** Sime W, Niu Q, Abassi Y, Masoumi KC, Zarrizi R, K hler JB, Kjellstr m S, **Lasorsa VA**, Capasso M, Fu H, Massoumi R. *Cell Death Dis*. 2018 May 1. PMID: 29686263. IF: 8.469.
- **A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma.** Calabrese FM, Clima R, Pignataro P, **Lasorsa VA**, Hogarty M, Castellano A, Conte M, Tonini GP, Iolascon A, Gasparre G, Capasso M. *Oncotarget*. 2016 Jun 24. PMID: 27351283. IF: 3.331.
- **FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.** Romano S, Simeone E, D'Angelillo A, D'Arrigo P, Russo M, Capasso M, **Lasorsa VA**, Zambrano N, Ascierto PA, Romano MF. *Cancer Immunol Immunother*. 2017 Apr 16. PMID: 28434031. IF: 6.968.
- **An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma.** Formicola D, Petrosino G, **Lasorsa VA**, Pignataro P, Cimmino F, Vetrella S, Longo L, Tonini GP, Oberthuer A, Iolascon A, Fischer M, Capasso M. *J Transl Med*. 2016 May 17. PMID: 27188717. IF: 8.44.
- **Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.** **Lasorsa VA**, Formicola D, Pignataro P, Cimmino F, Calabrese FM, Mora J, Esposito MR, Pantile M, Zanon C, De Mariano M, Longo L, Hogarty MD, de Torres C, Tonini GP, Iolascon A, Capasso M. *Oncotarget*. 2016 Mar 18. PMID: 27009842. IF: 3.331.

According to law 679/2016 of the Regulation of the European Parliament of 27th April 2016 and to art. 13 of Legislative Decree no. 196/03 (Italian Privacy Act), I hereby express my consent to the treatment of my personal data provided in this CV.

Napoli,

30/07/2025



A handwritten signature in black ink, appearing to read "Roberto Ferraro", is written over a horizontal line.